At a median follow-up time of 51 months, the median OS was inferior for patients with CDX2-negative tumours (N = 27) when compared with those with CDX2-positive CRC (N = 319): median 30 versus 53 months, respectively (Mantel-Cox log-rank test, p = 0.008; Figure 4A). The gene discussed is CDX2; the disease is colorectal carcinoma.